Please try another search
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Hans-Peter Hasler | 65 | 2018 | Independent Non Executive Chairman |
Rolf Karl-Heinz Hoffmann | 62 | 2018 | Independent Non-Executive Director |
Peter Llewellyn-Davies | - | 2016 | Independent Non-Executive Director |
Christian Schweiger | 55 | 2008 | Co-Founder & Non Executive Director |
Michael Stockham | - | - | Notable Scientific Advisory Board |
Christoph Gasche | - | - | Notable Scientific Advisory Board |
Jonathon Powell | - | - | Notable Scientific Advisory Board |
Gregory P. Madison | 54 | 2021 | CEO & Executive Director |
Maria Fabiana Lacerca-Allen | 54 | 2021 | Independent Non-Executive Director |
Anders Lundstrom | 59 | 2021 | Independent Non-Executive Director |
Geoffrey A. Block | 56 | - | Notable Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review